HT
AVIR icon

Headlands Technologies’s Atea Pharmaceuticals AVIR Stock Holding History

Headlands Technologies’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.3K Buy
+16,619
New +$82.7K 0.01% 669

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Headlands Technologies's AVIR Position: Q2 2026 in Review

Headlands Technologies opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 16,619 shares worth $77.3K. The stake represents 0.01% of the portfolio and ranks #669 among its holdings.

125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Headlands Technologies held 16,619 shares of Atea Pharmaceuticals worth $77.3K as of Q2 2026.
  • Atea Pharmaceuticals was a new Headlands Technologies position in Q2 2026.
  • Atea Pharmaceuticals made up 0.01% of Headlands Technologies's portfolio in Q2 2026, its #669 holding.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.